MetaCap

ALX Oncology (ALXO) vs Zentalis Pharmaceuticals (ZNTL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Zentalis Pharmaceuticals (ZNTL) has outperformed ALX Oncology (ALXO) over the past year, gaining 1.5% versus a loss of 25.9%. Over five years, ALXO leads with a -96.8% price change compared with -98.2% for ZNTL. ALX Oncology is the larger company by market cap ($137.0 million vs $133.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALXO-25.87%ZNTL+1.49%
+415%+178%-59%
Nov 21, 20251 yearNov 20, 2026
ALXO-97.23%ZNTL-98.25%
+14%-45%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALXO versus ZNTL key metrics
MetricALXOZNTL
Share price$1.06$1.36
Market cap$137.03M$133.64M
1-day change+3.92%0.00%
YTD return-6.19%+0.74%
1-year return-25.87%+1.49%
5-year return-96.84%-98.21%
EPS (TTM)$-0.87$-1.90
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Revenue growth (YoY)—-100.00%
Net income (latest FY)$-101.69M$-137.06M
52-week high$2.66$6.95
52-week low$0.862$1.30
Distance from 52-week high-60.15%-80.43%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+333.96%+447.06%
Average volume1.19M1.26M
Shares outstanding129.27M98.27M
Employees49106
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ZNTL has outperformed ALXO by 27.4 percentage points over the past year.

About ALX Oncology

ALXO stock →

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees

About Zentalis Pharmaceuticals

ZNTL stock →

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.

Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees

ALXO vs ZNTL FAQ

Which is bigger, ALX Oncology or Zentalis Pharmaceuticals?

ALX Oncology (ALXO) is larger, with a market capitalization of $137.03M compared with $133.64M for Zentalis Pharmaceuticals (ZNTL).

Which stock has performed better over the past year, ALXO or ZNTL?

ZNTL returned +1.49% over the past 12 months, compared with -25.87% for ALXO (price return, excluding dividends). Past performance does not predict future results.

Are ALX Oncology and Zentalis Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons